Tasly Pharmaceutical
10
88M
7
0.34
1
0.30
3
- Areas of investment
Summary
Tasly Pharmaceutical appeared to be the Corporate Investor, which was created in 1994. The fund was located in Asia if to be more exact in China. The main office of represented Corporate Investor is situated in the Tianjin.
The top amount of exits for fund were in 2018. Speaking about the real fund results, this Corporate Investor is 5 percentage points more often commits exit comparing to other organizations. Comparing to the other companies, this Tasly Pharmaceutical performs on 16 percentage points less the average number of lead investments. The high activity for fund was in 2018. Despite it in 2019 the fund had an activity. The fund is generally included in less than 2 deals every year. The usual things for fund are deals in the range of 50 - 100 millions dollars. The average startup value when the investment from Tasly Pharmaceutical is 100-500 millions dollars.
The fund has exact preference in some founders of portfolio startups. In case when startup counts 4 or 5+ of the founder, the chance for it to get the investment is meager. Among the most popular portfolio startups of the fund, we may highlight Ascletis, I-Mab Biopharma, Profusa. Among the most popular fund investment industries, there are Wellness, Medical Device. Besides, a startup needs to be aged 4-5 years to get the investment from the fund. For fund there is a match between the country of its foundation and the country of its the most frequent investments - China.
The standard case for the fund is to invest in rounds with 4-5 partakers. Despite the Tasly Pharmaceutical, startups are often financed by C-Bridge Capital, Tianyi Group, Shenghua Group. The meaningful sponsors for the fund in investment in the same round are C-Bridge Capital, WTT Investment, VT Ventures. In the next rounds fund is usually obtained by C-Bridge Capital, WTT Investment, Tally Capital.
Investments analytics
Analytics
- Total investments
- 10
- Lead investments
- 1
- Exits
- 3
- Rounds per year
- 0.34
- Follow on index
- 0.30
- Investments by industry
- Biotechnology (6)
- Medical (5)
- Health Care (4)
- Pharmaceutical (3)
- Product Research (3) Show 10 more
- Investments by region
-
- China (6)
- United States (3)
- France (1)
- Peak activity year
- 2018
- Number of Minotaurs
- 1
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 11
- Avg. valuation at time of investment
- 42M
- Group Appearance index
- 0.90
- Strategy success index
- 0.30
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| I-Mab Biopharma | 29 Jun 2018 | Biotechnology, Pharmaceutical, Product Research | Late Stage Venture | 220M | Shanghai, China |
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.